OpusPoint Partners is dedicated to launching new improvements in the areas of medicine and healthcare. The company’s financial investments in these areas will give emergent biotechnology and life science companies a head start to breaking new ground and the mentoring provided by OpusPoint Partners will pave an even path for these budding companies to reach the pinnacle of success.

It is the goal of OpusPoint Partners to find innovative alternatives in healthcare and medicine that are of betterment to the human race. Founded in 2009 by Michael Weiss and Lindsay Rosenwald, M.D., OpusPoint Partners has been on an influential and productive roll ever since. This is no surprise as both Weiss and Rosenwald are very knowledgeable in the spheres of biotech and life sciences, having founded and financed a multitude of like-minded research companies over the decades.

A solid case in point of the cofounders’ success in this realm can be noted with Lindsay Rosenwald’s creation of Cougar Biotechnology Inc. This Southern California biotech company primary focus is aimed at cancer drug research. Some of the drugs produced by this company showed promised during trials and garnered a great deal of attention from investors and researchers, including Johnson & Johnson. In 2009 the mega-conglomerate purchased Rosenwald’s biotech firm for approximately one billion dollars.

In order for OpusPoint Partners to have received the success that it has the company’s foundation would have to be knowingly built on transparency. Lindsay Rosenwald understands the importance of building an ethical groundwork with not only investors but also with the companies that he takes under the OpusPoint Partners wing. Full disclosure leads to comfortable investing and sustains the integrity of the company in the eyes of both financial backers and researchers alike.

Because of OpusPoint Partners strong ethical stance, the company is expanding to work with a variety of corporations, investors, and researchers who are itching for the opportunity to be included in the change that Lindsay Rosenwald and Michael Weiss are attempting to make in the realm of human health. Encouraging and financing emergent biotech companies is what Dr. Rosenwald does best, currently OpusPoint Partners is assisting nearly 20 life science and bio-tech companies attain their research goals and bring innovative drugs to trial in the hopes of making a monumental discovery in medicine.

With Lindsay Rosenwald at the helm of OpusPoint Partners, investors and biotech companies alike can feel confident that their venture needs are being met and that the company is copiously utilizing sound business acumen. Because of the company’s dedication to ethics within business Rosenwald and Weiss are able to offer their investors minimized investing risks that will continue to steadily grow over time. OpusPoint Partners ability to do this has been shown numerous times as the projections for the company’s growth has exceeded the projections for each year since its commencement.

Dr. Lindsay Rosenwald is ideally suited to co-lead OpusPoint Partners. His educational pursuits include obtaining a Bachelor of Science in Finance from Pennsylvania State University and then later a Doctor of Medicine from Temple University School of Medicine. Rosenwald has used this academic know how of two different industries to his advantage for the past 17 years as a biotechnology investor and trader on Wall Street as well as a founding numerous biotech companies.

Dr. Lindsay Rosenwald’s skills go beyond this; he has also effectively managed funds that ran into the billions for both the Aries Fund (1994 to 2007) and the Orion Fund (2002 to 2006). Under Rosenwald’s financial management the Aries Fund allocated in excess of one billion dollars for healthcare investments over the span of one year. The Orion Fund which is solely devoted to biotechnology investing also thrived under Dr. Rosenwald’s management.

The epicenter of OpusPoint Partners principles is to sustain a positive growth in the life science and biotech fields in manner that is genuine, honest, and promotes across the board ethical business standards. In today’s healthcare world where lines are sometimes blurred to maximize profit the OpusPoint Partners stands out as leader in business integrity and expects that the biotech companies that they back up to adhere to these same essential standards when it comes to research and drug clinical trials.

Lindsay Rosenwald and OpusPoint Partners intend to be a prominent force by being different from the typical biotechnology investing firms. The company, its investors, and employees all strive to maintain just dealings in all aspects of the business. And because of this the future indeed looks bright for the company, all of its associates, and the clinical sphere.

Michael Weiss and Dr. Lindsay Rosenwald both bring a lot to the table, their expertise has in the past helped to make great strides in the biotech and life science industry. With the over 40 years of combined experience both men offer investors and emergent companies in the biotech industry the assurance of quality, transparency, and innovation; all of which are key to bring about investment growth and industry change.

OpusPoint Partners with the expert guidance of Lindsay Rosenwald currently sponsors in excess of 20 up and coming biotech companies. This expansion in investments happened over a period of nearly two years and continues to steadily grow as well as yield encouraging returns in investments. It is the hope of all involved with OpusPoint Partners that true pioneering breakthroughs are made in medicine that will benefit all of society.

Dr. Lindsay Rosenwald dedicates a portion of his time outside of his occupation to the Republican Jewish Coalition sitting as a member on the Board of Directors. Rosenwald continues to actively develop his industry contacts in the biotechnology and financing realms. Sustained advancement of OpusPoint Partners is a likely reality under his proficient leadership.

Aries Fund · Republican Jewish Coalition

OpusPoint Partners:
Investing in the Future ofHealthcare and Life Sciences

At OpusPoint Partners,we have a vision for an amazing future for the life science and healthcare industry. We believe in that vision so strongly that we are investingmoney and time to advance life sciences and biotechnology. We also believe in a strong, healthy future for human kind. With proper funding and research, we know that the quality of healthcare can be catapulted to a new and more effective level.

A Vision for the Future of Healthcare
With this vision in mind, Michael S. Weiss and Dr. LindsayRosenwald created OpusPoint Partners in 2009. These men have over 40 years of combined experience in the fields of healthcare, life sciences and biotechnology investing. Both are creative thinkers who have founded a number of biotech companies over the years.

Dr. Lindsay A. Rosenwaldhas most recently founded Cougar Biotechnology Inc.,which is a Los Angeles-based firm that focuses on the field of oncology. Cougar’s oncology portfolio includes some promising experimental drugs effective in treatingnumerousforms of cancer. One of those in particular has drawn the interests of researchers and investors. It has proven to work well at treating late-stage prostate cancer. Dr. Lindsay Rosenwald negotiated a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars in July of 2009.

Achieving the Objectives
The objective of Lindsay Rosenwald and OpusPoint Partners is twofold: to move forward withintegrity in achieving long-term goals and short-termgains, and to build solid relationships in both the world of investing and biotechnology. By establishing strong relationships withother industry leaders who share similar values, they believe that these goals and objectives can be obtained without the sacrifice of their principles and standards.

For OpusPoint Partners, honest investing with full and open disclosure is more than just good business. This is a way of life.They currently work with a wide range of corporations to create a team approach to supporting emerging new businesses in an effort to reach critical goals. Dr. Lindsay Rosenwald and OpusPoint Partners have made a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.These pioneers of research and investment believe in a better future for us all; a future where diseases are diagnosed and treated by more effective methods.
At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, believe in a world where people’s lives and health are greatly improved. They believe in creating a future where mankind achieves a much stronger quality of life. Through thisunique vision they are making a true difference in theirworld. In order to attain this dream of a better tomorrow for us all, their journey often involves providing advisory services to start-up businesses. Sometimes it requires investing in publicly-traded companies.

Raising the Bar
Dr. Lindsay Rosenwald and OpusPoint Partners, is working to raise the bar for investors. Their efforts include advising emerging biotechnical research facilities. They believe that a strong moral compass along with sound business principles can significantly minimize risks and thereby maximize returns for investors and so far, this unique formula is proving to be successful.

For the past 17 years, Dr. Rosenwald has been a well-respected Wall Street biotechnology entrepreneur. His business ethics have not gone unnoticed. He has, in fact, been instrumental in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

An Innovative Business Philosophy
During his impressive twenty-year career, Dr. Lindsay Rosenwald has founded over fifty companies and managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. During the years of 2002 through 2006, he also managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

The philosophy behind OpusPoint Partners will be to build a successful life science and healthcare network that plays fair and does not take short cuts to reach its goals. Dr. Rosenwald and his associates know that the world we currently live in often provides too many opportunities for business leaders to use less than ethical tactics to try to manipulate outcomes of clinical trials and hence increase quarterly earnings.
OpusPoint Partners is a uniqueenterprise that continually reinforces its commitment to its employees and investors. Their promise is to deal fairly in all aspects of experimental drug trials. In the investigation and manufacture of experimental drugs, they are resolute about these vows.

The Benefits of Making the World a Better Place
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.
But revolutionizing these age-old medicaland healthcare techniques and procedures is no small task, nor is it for the faint of heart. In order to effect changes on such a grand scale requires commitment; it requires time and money. It also involves a strong resolve to work hard within the ethical boundaries that other drug research companies may have discarded in favor of better profits.

Dr. Rosenwaldunderscoresthe fact that over the past few years, projected goals have already been surpassed. By applying best practices and processes, OpusPoint Partners moves ahead earning superior, risk-adjusted returns and helpingto finance and support more than 20 companies in the past two years alone. This achievement is marked by a continuing commitment to the financial world and the world of drug research.

Credentials and Lifetime Achievements
Dr. LindsayRosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector.The future of OpusPoint Partners looks very promising with Dr. Rosenwald as its vanguard.

Lindsay Rosenwald · Lindsay Rosenwald Healthcare Firm · Lindsay Rosenwald Lifescience Investment Firm

OpusPoint Partners is an innovative new company with a unique vision for the future of the life science and healthcare industry. That vision includes some cutting edge technologies but also some forward thinking business philosophies.

As with alllofty visionssuchas this, itwill take immense commitment from quality entrepreneurs to accomplish. Michael S. Weiss and Dr. Lindsay Rosenwald created OpusPoint Partners in 2009 with the idea of combining their 40 years of experience and business acumen working toward revolutionizing the fields of healthcare, life sciences and biotechnology investing. Both these men are well equipped to do this job and have already founded a number of biotech companies over the years.

With so much at stake, OpusPoint Partners along with Dr. Lindsay Rosenwald, is working toward making those leaps to advance and even transform the world of life sciences and biotechnology investing. Rosenwald, along with his team at OpusPoint, believe in a future where mankind significantly improves the quality of healthcare, as well as healthcare investing.

Advancements in the Future of Healthcare
Recently, Dr. Lindsay A. Rosenwaldfounded Cougar Biotechnology Inc. This Los Angeles-based company focuses on the field of oncology. Their oncology portfolio includes some very promising experimental drugs, which are proving to be effective in treatingnumerousforms of cancer.

One in particular has caused some excitement and drawn the interests of researchers and investors. It is a new drug that has been proven to work well at treating late-stage prostate cancer. In July of 2009, Dr. Lindsay Rosenwaldwas able to negotiate a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars.

Realizing the Objectives
Lindsay Rosenwald and OpusPoint Partners believe they can continue to move forward with projects like these that alter healthcare significantly and produce results for the greater good of mankind. They achieve these goals with integrity, building solid relationships in both the world of investing and biotechnology.

Establishing robust relationships withother industry leaders who share similar values is a hallmark of the business strategy of both Dr. Lindsay Rosenwald and OpusPoint Partners. They believe in reaching goals and objectives through honesty, integrity and hard work. Their success has proven that you can obtain these objectives without the sacrifice ofprinciples and standards. Honest investing with full and open disclosure is more than just good business for OpusPoint Partners. This is the ideology they live by.

Creating New Partnerships for a Better Tomorrow
Dr. Lindsay Rosenwald and OpusPoint Partners currently work with a wide range of businesses and organizations to create a team approach for thesupport of emerging new businesses. They are making great strides toward building a powerful network of like-minded individuals who all possess a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.

With pioneers such as these in the areas of research and investment, you can be sure that thefuture of healthcare and life sciences will continue to flourish. These days, the medical field is well-aware of its need for diseases of all types to be diagnosed and treated by more effective methods. At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, know that the dream can become a reality with hard work and dedication.

The dream of a better tomorrow continues to be the fuel that fires this vision of a much stronger quality of life for us all. And thisunique vision of making a true difference in the world has become a driving force for Dr. Lindsay Rosenwald and OpusPoint Partners. History shows that dreams like this always take time, money and hard work, plus dedication from those involved.

Raising the Bar for Investors
Over the course of this journey, Dr. Lindsay Rosenwald and OpusPoint Partners must oftenprovide advisory services to start-up businesses. At times they also must invest in publicly-traded companies in order to move the vision forward.

One of their key objectives is to raise the bar for all investors. Whether working in the advisory capacity with emerging biotechnical research facilities or actually investing, OpusPoint followsa strong moral compass.With sound business principleslike these, the risks can be significantly minimizedand the returns for investors maximized. This uniqueformula has proven successful beyond anyone’s wildest dreams.

Utilizing Ethical Business Practices
The philosophy behind OpusPoint Partners is to build a positive and effective life science and healthcare network that plays fair and won’t take short cuts to reach its goals. Dr. Rosenwaldknows from experience, that today’s world often provides many opportunities for business leaders to use less than ethical tactics to try and manipulate outcomes of clinical trials with an eye toward greaterquarterly earnings. Does the end justify the means?

At OpusPoint Partners, the answer is a resounding no! This unique enterprise continually reinforces its commitment to its employees and investors to conduct business with higher standards than many of days gone by. In the investigation and manufacture of experimental drugs, they are resolute about this commitment to honest, above-board business dealings.

A Long and Fruitful Career
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.

Dr. Rosenwald, a well-respected Wall Street biotechnology entrepreneur, has worked for the past 17 years utilizing strong business ethics in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

Throughout an impressive twenty-year career, Dr. Lindsay Rosenwald has established over fifty companies. He also managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. From 2002 to 2006, hemanaged the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

Dr. Lindsay Rosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector. The future ofOpusPoint Partners indeed looks promising with Dr. Rosenwald at its helm.

Dr Lindsay Rosenwald · Lindsay Rosenwald · Lindsay Rosenwald New Firm

According to a new study data on abiraterone acetate, a novel discovery from J&J, patients with metastatic advanced prostate cancer lived nearly 4 months longer compared with patients treated with placebo. The data shows that abiraterone may become a new oncology compound that could change clinical practice and promote survival benefits in patients with prostate cancer.

Phase 3 study of patients with advanced prostate cancer, who were previously treated with other compounds, including chemotherapy and anti-hormonal therapy, on average, lived 14.8 months while those on prednisone/prednisolone plus a placebo lived 10.9 months. Those 3.9 months do not seem to make a big difference, but some analysts, including Lindsay Rosenwald of BioSciences investment bank and Johann de Bono of UK Institute of Cancer Research, believe that abiraterone is a great step forward in the treatment of prostate cancer, since only four drugs in the oncology history showed survival benefits before. The drug can even be compared to Roche’s Herceptin that helps in the treatment of breast cancer.

The Phase 3 trial results may alter the lives of men with advanced prostate cancer, since they had very poor diagnosis and almost no available treatment, especially after the tumor progressed after radio- or chemotherapy. The data of the trial was presented at the European Society for Medical Oncology (ESMO) congress and was found to be very promising.

Potential blockbuster

Because of a clear survival benefit, physicians and investors like Dr. Lindsay Rosenwald recommended that the patients treated with placebo and prednisone should be offered abiraterone acetate. According to some financial analysts, including Damien Conover, Lindsay Rosenwald and independent forecaster BioMedTracker, the annual abiraterone sales are expected to be around $1.5 billion by 2015.

After acquiring Cougar Biotechnology, Johnson & Johnson secured its access to abiraterone and planned to file sales applications in the United States and Europe by the end of 2010. Dr de Bono said that patients receiving abiraterone acetate had much less side effects than those patients treated with chemotherapy, although they did experience more side effects associated with prednisone/prednisolone. If approved, abiraterone will be tested in patients diagnosed with early-stage prostate cancer. And hopefully, the drug will make the difference.

Biotechnology · Lindsay Rosenwald